Table 2 Serum level of TLR-7 in urinary bladder cancer and urinary tract infection patients and control distributed according to some characteristics
Characteristic | Median (range); ng/ml | p (pc) | ||||
|---|---|---|---|---|---|---|
UBC (N = 66) | UTI (N = 40) | C (N = 48) | UBC vs. C | UTI vs. C | UBC vs. UTI | |
Total | 1.4 (0.1–22.2) | 8.1 (0.7–14.6) | 9.5 (1.9–25.1) | < 0.001 (S) | 0.089 (NS) | < 0.001 (S) |
Gender | ||||||
Male | 1.3 (0.1–22.1) | 7.1 (4.1–14.6) | 6.5 (1.9–25.1) | < 0.001 (S) | 0.564 (NS) | < 0.001 (S) |
Female | 1.6 (0.6–3.4) | 8.5 (0.7–14.5) | 11.7 (5.6–17.0) | < 0.001 (S) | 0.003 (S) | 0.001 (S) |
p (pc) | 0.827 (NS) | 0.654 (NS) | 0.002 (S) | |||
Age group | ||||||
< 48 years | 2.0 (0.1–22.2) | 8.3 (0.9–14.6) | 9.1 (1.9–25.1) | < 0.001 (S) | 0.199 (NS) | < 0.001 (S) |
≥ 48 years | 1.1 (0.1–9.2) | 7.2 (0.7–14.5) | 10.4 (6.9–13.9) | < 0.001 (S) | 0.343 (NS) | < 0.001 (S) |
p (pc) | 0.152 (NS) | 0.919 (NS) | 0.559 (NS) | |||
Cigarette-smoking | ||||||
Yes | 1.3 (0.1–22.2) | 7.1 (4.1–10.8) | 8.8 (1.9–25.1) | < 0.001 (S) | 0.387 (NS) | < 0.001 (S) |
No | 1.6 (0.1–7.9) | 8.5 (0.7–14.6) | 10.1 (2.9–17.0) | < 0.001 (S) | 0.134 (NS) | < 0.001 (S) |
p (pc) | 0.933 (NS) | 0.754 (NS) | 0.668 (NS) | |||
Alcohol-consuming | ||||||
Yes | 2.7 (0.1–9.8) | 7.0 (6.8.2–7.2) | 4.6 (1.9–7.2) | 0.309 (NS) | 0.533 (NS) | 0.173 (NS) |
No | 1.1 (0.1–22.2) | 8.3 (0.7–14.6) | 10.4 (2.0–25.1) | < 0.001 (S) | 0.04 (NS) | < 0.001 (S) |
p (pc) | 0.023 (NS) | 0.785 (NS) | 0.007 (S) | |||
Family history | ||||||
Yes | 1.0 (0.1–6.7) | |||||
No | 1.6 (0.1–22.2) | |||||
p (pc) | 0.397 (NS) | |||||
Clinical stage | ||||||
I–II | 1.3 (0.1–22.2) | |||||
III–IV | 2.1 (0.1–9.8) | |||||
p (pc) | 0.193 (NS) | |||||
Tumor invasiveness | ||||||
Superficial | 1.1 (0.1–6.7) | |||||
Invasive | 1.9 (0.1–22.2) | |||||
p (pc) | 0.086 (NS) | |||||
Type of therapy | ||||||
Untreated | 1.1 (0.1–6.7) | |||||
Methotrexate | 1.8 (0.1–22.2) | |||||
BCG | 1.3 (0.1–7.9) | |||||
p (pc) | 0.464 (NS) | |||||